13F Holdings
中文EN

ALDX Aldeyra Therapeutics, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1341235 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY55.7%
TTM EPS YoY57.5%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-45.3%
ROA-31.6%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets18.8%
Debt / equity0.00x
Current ratio5.45x
Interest coverage-21.39x

Cash quality & payout

Operating cash flow / net income1.00x
Accruals ratio-0.0%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue—————
R&D expense$25.66M$48.22M$29.46M$47.31M$44.94M
SG&A expense$9.60M$11.89M$13.34M$15.37M$11.28M
Operating income-$35.27M-$60.12M-$42.79M-$62.68M-$56.22M
Interest expense$1.91M$1.93M$2.07M$1.69M$1.74M
Pretax income$33.85M$55.85M——-$57.78M
Income tax$0$1,000$0$0$0
Net income-$33.85M-$55.85M-$37.54M-$62.02M-$57.78M
EBITDA-$35.01M-$59.87M-$42.53M-$62.42M-$55.96M
EPS (basic)-0.56-0.94-0.64-1.06-1.07
EPS (diluted)-0.56-0.94-0.64-1.06-1.07
Weighted avg. shares (diluted)60.06M59.48M58.94M58.41M54.04M
Balance sheet
Cash & equivalents$70.04M$54.53M$142.82M$144.42M$229.79M
Short-term investments$0$46.62M$0$29.88M$0
Current assets$71.78M$104.07M$147.81M$181.02M$232.75M
PP&E, net$0$0$5,764$19,279$32,487
Total assets$72.06M$104.61M$148.33M$181.29M$233.14M
Current liabilities$27.81M$18.60M$22.26M$15.36M$11.77M
Short-term debt$15.25M$31,372$15.15M$911,763—
Long-term debt$0$15.00M$0$14.92M$15.50M
Total debt$15.25M$15.03M$15.15M$15.83M$15.50M
Total liabilities$27.81M$33.60M$28.53M$30.28M$27.40M
Shareholders' equity$44.25M$71.00M$119.80M$151.01M$205.74M
Net debt-$54.79M-$39.50M-$127.68M-$128.58M-$214.29M
Shares outstanding60.16M59.65M59.20M58.56M58.08M
Cash flow statement
Operating cash flow-$33.35M-$43.21M-$30.33M-$56.64M-$42.56M
Capital expenditure——$0$16,317$7,806
Free cash flow——-$30.33M-$56.65M-$42.56M
Investing cash flow$47.74M-$44.92M$30.00M-$29.95M-$7,806
Financing cash flow$1.12M-$171,422-$1.27M$1.22M$194.50M
Depreciation & amortization$251,993$249,623$262,780$258,707$264,180
Stock-based compensation$6.09M$7.97M$5.75M$8.29M$7.11M

Free plan shows the latest 5 periods; Pro shows all 13 🔒

· This company does not report gross profit in XBRL.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.